Clinical trials in Heilbronn – page 26

987 clinical trials in Heilbronn, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Heilbronn at a glance

987

clinical trials

Research sites1

Quick filters

987 trials in Heilbronn

Open in trial search

Synovial sarcoma+1

Recruiting

Study on Pasireotide for Patients with Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Registered drugNo placebo

Study on Pasireotide for Patients with Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Pasireotide
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Follicular lymphoma

Recruiting

Study on Early Stage Follicular Lymphoma: Evaluating Radiotherapy with Rituximab or Obinutuzumab for Patients with Early Stage Nodal Follicular Lymphoma

Registered drugNo placebo

Study on Early Stage Follicular Lymphoma: Evaluating Radiotherapy with Rituximab or Obinutuzumab for Patients with Early Stage Nodal Follicular Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Alport's syndrome

Recruiting

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug

Germany

Participants:0–17 years · 18–64 years
Substances:Dapagliflozin
Sponsor:Universitaetsmedizin Goettingen

Contact Research Centre

Hepatocellular carcinoma

Recruiting

Study on Fecal Microbiota Transfer with Vancomycin, Atezolizumab, and Bevacizumab for Patients with Advanced Liver Cancer

Registered drug

Study on Fecal Microbiota Transfer with Vancomycin, Atezolizumab, and Bevacizumab for Patients with Advanced Liver Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Oxaliplatin
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Glioblastoma

Recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heilbronn

What the registry says about research in the country

01 Blood Cancers

Innovative trials focusing on Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia, testing novel drug combinations to improve patient outcomes. Research includes evaluating treatments for both adult and pediatric patients with various forms of leukemia.

Novel drug combinations for AML treatment
Targeted therapies for specific genetic mutations
Pediatric leukemia protocols

Studies aim to enhance survival rates and develop more effective treatment strategies for blood cancer patients.

02 Breast Cancer Research

Comprehensive studies addressing different types of breast cancer, particularly focusing on triple-negative breast cancer and HER2-positive disease. Research includes both early-stage and metastatic disease treatments.

Advanced therapeutic approaches for TNBC
Adjuvant therapy optimization
Personalized treatment strategies

Trials evaluate novel drug combinations and targeted therapies to improve patient outcomes.

03 Gastrointestinal Oncology

Research focusing on various digestive system cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Studies evaluate both early-stage and advanced disease treatments.

Advanced gastric cancer therapies
Preoperative treatment strategies
Novel combination approaches

Investigations aim to improve surgical outcomes and treatment effectiveness for GI cancers.

Back to Germany All countries